Cue Biopharma Inc. (CUE)
CUE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$19.57
-20.48% on the day
Market cap
$142.2M
Micro cap
Revenue · 2025
$27.5M
+195.7% on 2024
Net income · 2025
-$26.6M
-96.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | CUE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001645460 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $27.5M |
| Net income | -$26.6M |
| Operating income | -$26.6M |
| Net margin | -96.9% |
| Operating margin | -96.7% |
| Revenue growth | +195.7% |
| Cash | $27.1M |
| Total assets | $42.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-12 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-09-21 |
| Latest proxy | DEF 14A | 2026-05-21 |
Source: SEC EDGAR submissions feed, 549 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BGM | BGM Group Ltd. | $10.48 | +2.75% | $140.0M |
| TLSA | Tiziana Life Sciences Ltd. Common Shares | $1.09 | 0.00% | $138.7M |
| ANTX | AN2 Therapeutics Inc. | $3.60 | -16.28% | $135.9M |
| NBP | NovaBridge Biosciences | $1.29 | -2.27% | $148.8M |
| ALXO | ALX Oncology Holdings Inc. | $0.9796 | -22.25% | $135.5M |
| MSLE | Satellos Bioscience Inc. | $7.04 | -1.81% | $149.4M |
| NKTX | Nkarta Inc. | $2.10 | -3.23% | $150.4M |
| RNA | Atrium Therapeutics Inc. | $7.75 | -5.60% | $132.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier